| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e1cfdcb6b34b2891165ada5bb19ff14 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2005-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9496fb3c3f83423f898b38192f6132e7 |
| publicationDate |
2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005277591-A1 |
| titleOfInvention |
Use of RPL41 to treat infections and inhibit cancer |
| abstract |
The present invention relates to peptides of RPL41 and their use in the treatment of cancer and microbial infections. It is contemplated that modified forms of RPL41, including substitutional variants and mimetics, will be used. Mono- and combination therapies with other cancer treatments are contemplated. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007022076-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008221150-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007022076-A2 |
| priorityDate |
2004-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |